First Manhattan’s Cytokinetics CYTK Stock Holding History

First Manhattan’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-18,288	Closed	-$147K	–	1377
2019 Q1	$147K	Buy	+18,288	New	+$134K	﹤0.01%	764

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

First Manhattan's CYTK Position: Q2 2019 in Review

First Manhattan sold out of Cytokinetics (CYTK) in Q2 2019, closing a stake of 18,288 shares — an estimated $147K sold.

First Manhattan first reported a position in CYTK in Q1 2019 and held it in 1 quarter. The position peaked at $147K in Q1 2019. 134 funds tracked by Wall St. Rank hold CYTK as of Q2 2019.

First Manhattan reported no remaining Cytokinetics position as of Q2 2019 after selling out during the quarter.
First Manhattan sold 18,288 Cytokinetics shares in Q2 2019, an estimated $147K.
First Manhattan first reported a position in Cytokinetics in Q1 2019 and held it in 1 quarter.
First Manhattan's Cytokinetics position peaked at $147K in Q1 2019.
134 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2019.

Based on First Manhattan's 13F filing for Q2 2019, filed 16 Aug 2019.